ARVO

Oculis announces positive data from phase 2 trials with novel topical TNF alpha antagonist OCS-02 for DED, acute anterior uveitis

Oculis reported positive data from two of its clinical proof-of-concept phase 2 trials for OCS-02, a novel topical anti-TNF alpha antibody fragment candidate, for the treatment of dry eye disease and acute anterior uveitis.

Gene therapy prompts foveal morphologic changes in LCA

Friederike Kortuem, MD, MSc, discusses how treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.

Analyzing 24-month data of the PALADIN study

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Measuring visual fields with a cloud-based AI platform

May 07, 2021

Mohamed Abou Shousha, MD, PhD, and Richard Parrish II, MD, discuss their ARVO 2021 presentation regarding a study analyzing visual field measurements using the Heru Visual Field Multi-platform application downloaded on two different commercially available augmented reality devices.

Linking patient imaging data to AAO IRIS Registry

May 06, 2021

Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.